September 2024 in “Current Oncology” This review discusses the common occurrence of docetaxel-induced hair loss in cancer patients, including permanent cases, and highlights current and experimental strategies like scalp cooling, minoxidil, and new clinical trials for managing and preventing this side effect.
May 2015 in “Cancer research” This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.
January 2019 in “Przegląd Dermatologiczny” This article reviews clinical issues and dermatologist perspectives on managing periungual lesions in patients undergoing docetaxel chemotherapy, but it reports no new clinical outcomes.
14 citations
,
October 2003 in “Annals of Oncology” In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.
12 citations
,
January 2014 in “Journal of international medical research” This study found that, among patients with NSCLC after EGFR-TKI failure, pemetrexed is as effective as docetaxel but has fewer side effects, suggesting it may be a suitable salvage chemotherapy option.